Treatment of vaginal mycoses, bacterial vaginoses, and other forms of the vaginitis (inflammation of the vagina) by clinoptilolite having a particle size of between 0.2 and 10 μm. Clinoptilolite, when used externally, is effective in the treatment of these vaginal disorders in mammals and humans, and also for restoring a healthy vaginal microbiota. The clinoptilolite may be used with one or more of the following adjuvants: pharmaceutically acceptable carrier materials, viable microorganisms and/or extracts thereof, nutrients for the healthy vaginal microbiota (e.g. lactose, etc.), and/or substances which favorably influence the vaginal environment for the healthy vaginal microbiota (e.g. estradiol, organic acids, etc.). The composition used may be applied locally, preferably in one of the following administration forms: foam, suppository, vaginal tablet, ovule, gel, aerosol, powder, rinse, douche, cream/ointment, or suspension.
